Title: PRESENT AND FUTURE COLLABORATIVE DRUG DISCOVERY INFORMATICS INNOVATIONS

Biography:

Barry A. Bunin, Ph.D. is the CEO of Collaborative Drug Discovery. Dr. Bunin has overseen $50 million in business transactions over the last two decades. Prior to CDD, he was an Entrepreneur in Residence with Eli Lilly & Co. Dr. Bunin is on a patent for Kyprolis™ (Carfilzomib for Injection) — a selective proteasome inhibitor that received accelerated FDA approval for the treatment of patients with multiple myeloma that was widely viewed as the centerpiece of Amgen’s $10.4 Billion acquisition of Onyx Pharmaceuticals

Abstract

Collaborative Drug Discovery (CDD) provides a whole solution for today’s biological and chemical data needs, differentiated by ease-of-use and superior collaborative capabilities.  CDD Vault^® software includes Activity & Registration, Visualization, Inventory, and ELN capabilities.   Researchers can archive, mine, and securely collaborate within CDD Vault.  Collaborative hypothesis generation and evaluation allow multiple perspectives for multi-parameter optimization.

CDD’s Research Informatics Group invents bleeding edge technologies.  For example, the recently developed BioHarmony data store provides real-time semantic drug reports online at www.biometadata.com.  In addition, BioHarmony Annotator allows more sophisticated assay registration and management. 

Case studies will be shared from industry (Jubilant Biosys), government (NIH Neuroscience Blueprint), non-profit (Gates Foundation), and numerous leading academic collaborations.